Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Bart Van WijmeerschBarry A SingerAaron BosterSimon A BroadleyÓscar FernándezMark S FreedmanGuillermo IzquierdoJan LyckeCarlo PozzilliBasil SharrackBrian SteingoHeinz WiendlSibyl WrayTjalf ZiemssenLuke ChungDavid H MargolinKarthinathan ThangaveluPatrick VermerschPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)
CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.